Telegraft Hub Home

Welcome to the ISCT Telegraft Hub

The New York Times recently reported that Kendric Cromer, a 12-year-old boy in Washington, D.C., is the first commercial patient to begin the newly FDA-approved bluebird bio’s Sickle Cell Gene Therapy. “Sickle cell always steals my dreams and interrupts all the things I want to do. I want to be cured,” he said.  Kendric — whose family’s health insurance agreed to cover the procedure — began his treatment on May 1st, 2024, at Children’s National Hospital in Washington. Kendric’s journey and his chance of a one-and-done cure of a dreadful condition with a CGT (Cell and Gene Therapy) exemplify precisely what we as members of ISCT aspire to develop and deploy for catastrophic disease with unmet medical needs. Read More

THERE IS THIS EASE, THIS SIMPLICITY, THIS INSPIRATION, WHEN WE WRITE ABOUT REVOLUTIONS. “Chimeric antigen receptor (CAR) T cell therapies are here to change the world,” we say (and have been saying for over a decade – in grants, in lay articles, in interviews). The cancer-stricken can now be cancer-free. Every disease can potentially be targeted: HIV, autoimmune disease, many others. But the impact of revolutions is only as good as the governing that happens after – the boring, tedious, trial-and-error part of making the dream available to all. Read More

For first-time – and even repeat – attendees to an ISCT Annual Meeting, the entire process of preparing for the conference, navigating the meeting, and actually making meaningful connections with other attendees can be daunting. To help alleviate these fears and offer helpful guidance, for this month’s Member Spotlight, the Telegraft Editorial Board’s own Ashley Krull, Ph.D., facilitated a conversation between experienced and novice conference attendees from the Cellular Therapy Laboratory at The Ohio State University James Cancer Hospital in Columbus, Ohio. Read More


ISCT Calendar

Upcoming Events


ISCT 2023 Annual Meeting